SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-17-202470
Filing Date
2017-06-13
Accepted
2017-06-13 16:21:51
Documents
54
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d386501d10q.htm 10-Q 545958
2 EX-31.1 d386501dex311.htm EX-31.1 8991
3 EX-31.2 d386501dex312.htm EX-31.2 9022
4 EX-32.1 d386501dex321.htm EX-32.1 4006
  Complete submission text file 0001193125-17-202470.txt   2664767

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ovid-20170331.xml EX-101.INS 319082
6 XBRL TAXONOMY EXTENSION SCHEMA ovid-20170331.xsd EX-101.SCH 33652
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ovid-20170331_cal.xml EX-101.CAL 40350
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ovid-20170331_def.xml EX-101.DEF 139404
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20170331_lab.xml EX-101.LAB 274683
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20170331_pre.xml EX-101.PRE 218103
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38085 | Film No.: 17909104
SIC: 2834 Pharmaceutical Preparations